Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

GROWTH HORMONE SUPPORTFDA-ApprovedPopularPopular · Visceral Fat & Lean

Tesamorelin

GHRH Analog · 10mg

Vial size

Status

FDA-Approved

Route

SubQ

Half-life

~8 minutes plasma

Class

GHRH analog

MechanismGHRH Receptor Agonism

Cohort128 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$100 USD/vial

À-la-carte: $110 USD/vial · Save 9%

Vials per allocation

Member total (1×)$100

À-la-carte total$110

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

GHRH analogue with regulatory-approved evidence for visceral adipose reduction (Falutz et al., NEJM 2007). Used in V-03 for lean-mass preservation during metabolic protocols, and offered as the V-G1 cutting variant for patients whose specific clinical goal is central or visceral fat reduction. Considered the cleaner physiological choice over sustained-action GH secretagogues (e.g. CJC-with-DAC) for patients who want pulsatile, indication-supported GH-axis intervention. Physician-supervised allocation only.

GHRH Analog · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Used inV-Series

V-03

Metabolic - Weight & Blood Sugar

Popular · GLP-1 + Lean Mass

V-G1

Build - Lean Mass & Sleep Quality

Popular · GH-Axis Recovery

Tesamorelin · Growth hormone support

◆ Certificate of Analysis · Tesamorelin

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Batch 001 · lot VL-TES-2026-07A

Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.

Lot · Tesamorelin-2026-07-30

97.423%

Labeled

5 mg

Actual (HPLC)

4.73 mg

Method

HPLC + MS

Tested

Jul 30, 2026

Endotoxin

not tested for this lot

Heavy metals

not tested for this lot

Verify independently at janoshik.com/verificationPurity - code 9PCF8V7IKJBR

◉

Clinical Overview

Tesamorelin

Tesamorelin is a 44-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). FDA-approved (as Egrifta) for HIV-associated lipodystrophy, where it reduces visceral adipose tissue while preserving lean mass.

✦

Endogenous GH Release

GHRH-receptor agonist; stimulates natural pulsatile GH secretion.

❤

Metabolic Effects

FDA-approved for HIV-lipodystrophy; visceral-fat effects.

◈

Physiological Pattern

Preserves natural feedback vs. exogenous GH.

◈

Mechanism

How It Works

Binds GHRH receptors in the anterior pituitary, stimulating endogenous growth hormone secretion in physiological pulses. Distinct from exogenous GH administration in preserving the natural pulsatile pattern.

✚

Patient Bloodwork Guide

Bloodwork for Growth-Hormone Protocols

GHRH / GHRP secretagogues - Tesamorelin, CJC-1295, Ipamorelin, V-G1

These protocols gently restore your body’s own pulsing release of growth hormone rather than replacing it. Because growth hormone also affects blood sugar, monitoring confirms two things: that it is working, and that it is doing so safely.

Incremental approach. Vivre starts below the standard dose and advances only on tolerance. This monitoring is the safety scaffold for that conservative approach.

Is it working? (Efficacy)

IGF-1The main signal of your overall growth-hormone output across the day.

IGFBP-3The protein that carries IGF-1 - measured alongside it for a clearer picture of how much is active.

Blood sugar & metabolism (watch closely)

Fasting insulinThe earliest warning sign of insulin resistance - it moves before blood sugar does.

HbA1cYour average blood sugar over ~3 months. Especially relevant with Tesamorelin.

Fasting glucoseA routine blood-sugar check.

Keeping side effects in check

ProlactinIpamorelin (the one Vivre uses) is highly selective and rarely affects this; checked as good practice.

Cortisol (AM)A stress-hormone check included for completeness.

Overall safety

hs-CRPA sensitive inflammation marker - confirms recovery, not strain.

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

Baseline (before you start)Full panel - your natural starting point.

Mid-cycle (week 6–8)IGF-1, fasting insulin, prolactin/cortisol - confirm it works, catch sugar drift early.

Post-cycle (4 weeks off)IGF-1 and fasting insulin - confirm natural production recovers.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	GHRH analogue
Mechanism	GHRH-receptor agonism; stimulates endogenous GH/IGF-1 - well-characterised
Terminal half-life	Short (~25–40 min) but pharmacodynamic effect outlasts plasma presence
Metabolism	Peptidase degradation
Evidence base	Strong - approved for a specific indication (HIV-associated lipodystrophy)
Regulatory status	Approved for a specific indication; other use physician-supervised only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Well-characterised approved-class GHRH analogue. Educational only; treatment physician-determined.

Clinical Literature

Peer-Reviewed References

Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV

Falutz J, Allas S, Blot K, et al. · 2007 · New England Journal of Medicine 2007;357:2359–2370

▾

Findings

Pivotal Phase 3 RCT in HIV-associated lipodystrophy over 26 weeks. Tesamorelin produced selective reduction in visceral adipose tissue versus placebo, with improvements in lipid profile and no significant glycaemic worsening at the studied dose. This trial supported the FDA approval for the lipodystrophy indication. Use outside this indication is off-label.

View on publisher ↗

Tesamorelin has well-characterised evidence for visceral adipose reduction in its approved indication. Use in healthy adults for body composition is off-label and conducted under physician supervision with explicit consent.

◇

Clinical Applications

Indications

Visceral fat reduction
Lean mass preservation during weight loss
Component of metabolic-aesthetic protocols (V-03)
Age-related GH decline (off-label)

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~8 minutes plasma (FDA label, single 1.4mg dose, healthy subjects). Up to ~26-38 minutes after multi-day administration. Biological GH/IGF-1 effects persist far longer through downstream GH pulse cascade.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

FDA-approved with established trial data. Off-label longevity use is increasingly studied.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

▣

Featured In

V-Series Protocols Including Tesamorelin

◎

Commonly Paired

Compounds Often Prescribed With Tesamorelin

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Incretin Mimetic

Tirzepatide

Base Form · 10mg

◆ metabolic adjunct

Tesamorelin's visceral-fat indication complements incretin-class therapy for body composition outcomes during metabolic protocols. Standard pairing in Vivre's V-03.

View Tirzepatide detail →

Cytoprotective Peptide

BPC-157

Base Form · 5mg

◆ recovery support

BPC-157 co-allocated during GH-axis intervention to support gastric tolerance and systemic recovery signal.

View BPC-157 detail →

READY TO PROCEED

Start with the Biological Audit

Tesamorelin is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$100 USD/vial

Tesamorelin · Member rate